AXQ Capital’s Sarepta Therapeutics SRPT Stock Holding History

AXQ Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$862K	Sell	47,974 -50,238	-51%	-$950K	0.09%	321
2026 Q1	$2.14M	Buy	98,212 +77,965	+385%	+$1.51M	0.28%	97
2025 Q4	$436K	Buy	20,247 +5,628	+38%	+$119K	0.1%	325
2025 Q3	$282K	Sell	14,619 -39,088	-73%	-$697K	0.11%	336
2025 Q2	$918K	Buy	53,707 +40,878	+319%	+$1.74M	0.3%	98
2025 Q1	$819K	Buy	+12,829	New	+$1.35M	0.33%	89
2023 Q2	–	Sell	-10,900	Closed	-$1.5M	–	541
2023 Q1	$1.5M	Buy	+10,900	New	+$1.41M	0.6%	27

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AXQ Capital's SRPT Position: Q2 2026 in Review

AXQ Capital reduced its Sarepta Therapeutics (SRPT) stake by 51% in Q2 2026, selling an estimated $950K and leaving 47,974 shares worth $862K. The position accounts for 0.09% of the portfolio, ranked #321.

AXQ Capital first reported a position in SRPT in Q1 2023 and has held it in 7 quarters since. The position peaked at $2.14M in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

AXQ Capital held 47,974 shares of Sarepta Therapeutics worth $862K as of Q2 2026.
AXQ Capital sold 50,238 Sarepta Therapeutics shares in Q2 2026, an estimated $950K.
Sarepta Therapeutics made up 0.09% of AXQ Capital's portfolio in Q2 2026, its #321 holding.
AXQ Capital first reported a position in Sarepta Therapeutics in Q1 2023 and has held it in 7 quarters since.
AXQ Capital's Sarepta Therapeutics position peaked at $2.14M in Q1 2026.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.